Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Department of Clinical Science, University of Bergen, Bergen, Norway.
Infect Immun. 2019 May 21;87(6). doi: 10.1128/IAI.00219-19. Print 2019 Jun.
, one of the most common protozoal infections of the human intestine, is an important worldwide cause of diarrheal disease, malabsorption, malnutrition, delayed cognitive development in children, and protracted postinfectious syndromes. Despite its medical importance, no human vaccine is available against giardiasis. A crude veterinary vaccine has been developed, and experimental vaccines based on expression of multiple variant-specific surface proteins have been reported, but poorly defined vaccine components and excessive antigen variability are problematic for pharmaceutical vaccine production. To expand the repertoire of antigen candidates for vaccines, we reasoned that surface proteins may provide an enriched source of such antigens since key host effectors, such as secretory IgA, can directly bind to such antigens in the intestinal lumen and interfere with epithelial attachment. Here, we have applied a proteomics approach to identify 23 novel surface antigens of that show >90% amino acid sequence identity between the two human-pathogenic genetic assemblages (A and B) of the parasite. Surface localization of a representative subset of these proteins was confirmed by immunostaining. Four selected proteins, uridine phosphorylase-like protein-1, protein 21.1 (GL50803_27925), α1-giardin, and α11-giardin, were subsequently produced in recombinant form and shown to be immunogenic in mice and -infected humans and confer protection against infection upon intranasal immunization in rodent models of giardiasis. These results demonstrate that identification of conserved surface antigens provides a powerful approach for overcoming a key rate-limiting step in the design and construction of an effective vaccine against giardiasis.
贾第虫病是人类肠道最常见的原生动物感染之一,是全球范围内引起腹泻病、吸收不良、营养不良、儿童认知发育延迟和感染后长期综合征的重要原因。尽管它具有重要的医学意义,但目前还没有针对贾第虫病的人类疫苗。已经开发出一种粗制的兽医疫苗,并且已经报道了基于多种变异特异性表面蛋白表达的实验性疫苗,但疫苗成分定义不明确和抗原变异性过大是疫苗生产的问题。为了扩大疫苗抗原候选物的范围,我们推断表面蛋白可能是此类抗原的丰富来源,因为关键的宿主效应物,如分泌型 IgA,可以直接结合肠道腔中的此类抗原,并干扰上皮附着。在这里,我们应用蛋白质组学方法鉴定了 23 种新型表面抗原,这些抗原在寄生虫的两种人类致病遗传组合体(A 和 B)之间具有 >90%的氨基酸序列同一性。通过免疫染色证实了这些蛋白质的代表性亚组的表面定位。随后,以重组形式生产了 4 种选定的蛋白质,即尿苷磷酸化酶样蛋白-1、蛋白 21.1(GL50803_27925)、α1-贾第虫和α11-贾第虫,并在感染的人类和感染的小鼠中证明了它们的免疫原性,并在贾第虫病的啮齿动物模型中通过鼻内免疫赋予了对 感染的保护。这些结果表明,鉴定保守的表面抗原为克服针对贾第虫病的有效疫苗设计和构建中的关键限速步骤提供了一种强大的方法。